In September 1997, the FDA asked Wyeth-Ayerst Laboratories, the manufacturer of Redux and Pondimin, to issue a recall for both drugs because of their association with valvular heart disease. Wyeth agreed to a $1.28 billion Fen-Phen settlement in May 2006 with 40,000 patients who used the drugs and developed heart valve damage. However, patients who used Fen-Phen and developed PPH were not included in this settlement, and may still be eligible to file a lawsuit.
Fen-Phen users with PPH may still be elligible to file a lawsuit
Published December 4, 2008 News , Recall Leave a CommentTags: Fen-Phen, PPH, primary pulmonary hypertension, Wyeth
0 Responses to “Fen-Phen users with PPH may still be elligible to file a lawsuit”